Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$62.56 +0.7%	$64.75	$52.50 ▼ $77.00	$1.36B	0.55	328,099 shs	150,686 shs
OCUL Ocular Therapeutix	$8.73 -2.5%	$7.65	$5.11 ▼ $11.77	$1.39B	1.42	1.62 million shs	1.10 million shs
TVTX Travere Therapeutics	$14.50 -2.9%	$16.87	$6.80 ▼ $25.29	$1.29B	0.75	1.61 million shs	1.58 million shs
YSB YS Biopharma		$1.25	$0.35 ▼ $1.78	$344.32M	0.51	172,401 shs	63,510 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-1.05%	+3.74%	+0.19%	-0.59%	-3.25%
OCUL Ocular Therapeutix	+1.47%	+5.79%	+27.86%	+15.93%	+81.54%
TVTX Travere Therapeutics	+2.89%	+1.49%	-28.65%	-24.28%	+103.54%
YSB YS Biopharma	0.00%	0.00%	0.00%	0.00%	+424.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	4.1797 of 5 stars	3.5	1.0	0.0	3.3	2.4	3.3	1.3
OCUL Ocular Therapeutix	3.8268 of 5 stars	3.4	1.0	0.0	4.1	3.0	2.5	0.0
TVTX Travere Therapeutics	2.5061 of 5 stars	4.4	1.0	0.0	0.0	2.0	0.8	0.6
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	28.08% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	86.14% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	121.67% Upside
YSB YS Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest YSB, TVTX, OCUL, and ANIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$674.07M	2.01	$6.93 per share	9.03	$21.13 per share	2.96
OCUL Ocular Therapeutix	$59.65M	23.32	N/A	N/A	$0.79 per share	11.05
TVTX Travere Therapeutics	$273.53M	4.71	N/A	N/A	$2.67 per share	5.43
YSB YS Biopharma	$560.76M	0.00	N/A	N/A	$1.14 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$18.78M	-$1.27	N/A	14.86	N/A	-1.28%	15.87%	6.88%	8/5/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	7/30/2025 (Estimated)
YSB YS Biopharma	-$21.17M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest YSB, TVTX, OCUL, and ANIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.52	2.74	1.97
OCUL Ocular Therapeutix	0.19	13.01	12.94
TVTX Travere Therapeutics	24.96	1.71	1.68
YSB YS Biopharma	0.26	0.94	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
OCUL Ocular Therapeutix	59.21%
TVTX Travere Therapeutics	N/A
YSB YS Biopharma	52.64%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	12.70%
OCUL Ocular Therapeutix	2.30%
TVTX Travere Therapeutics	4.19%
YSB YS Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	18.36 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable
YSB YS Biopharma	773	93.06 million	N/A	Not Optionable

YSB, TVTX, OCUL, and ANIP Headlines

Recent News About These Companies

YS Life

October 25, 2024 | yourstory.com

LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

October 3, 2024 | finanznachrichten.de

LakeShore changes CEO with new executive appointments

September 5, 2024 | thepharmaletter.com

LakeShore Biopharma Co Ltd Ordinary Shares LSB

August 17, 2024 | morningstar.com

LSB LakeShore Biopharma Co., Ltd

July 20, 2024 | seekingalpha.com

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News Summary

July 19, 2024 | benzinga.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | finanznachrichten.de

YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting

May 22, 2024 | finanznachrichten.de

YS Biopharma Announces Results of Extraordinary General Meeting

May 21, 2024 | prnewswire.com

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

May 7, 2024 | prnewswire.com

With 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's future

May 7, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | finanznachrichten.de

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | prnewswire.com

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript

April 22, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

April 19, 2024 | markets.businessinsider.com

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

April 18, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

YSB, TVTX, OCUL, and ANIP Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$62.56 +0.44 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$62.47 -0.09 (-0.14%)

As of 04:04 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Ocular Therapeutix NASDAQ:OCUL

$8.73 -0.22 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$8.72 -0.01 (-0.06%)

As of 04:36 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$14.50 -0.44 (-2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$14.50 +0.01 (+0.03%)

As of 04:23 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

YS Biopharma NASDAQ:YSB

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time